214 related articles for article (PubMed ID: 32324296)
21. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
[TBL] [Abstract][Full Text] [Related]
22. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
24. Monitoring Treatment-Free Remission by Droplet Digital PCR in CML Patients with Deep Molecular Response to Tyrosine Kinase Inhibitor: An Analysis Based on Real-World Data.
Zhu G; Yang Y; Wang H; Xie J; Hu J; Guo W; Zhang L; Liu Z; Chen X; Chang J; Xu J; Tan Y
Ann Clin Lab Sci; 2020 Sep; 50(5):591-599. PubMed ID: 33067205
[TBL] [Abstract][Full Text] [Related]
25. A Case Report of Kidney Transplantation in a Patient With Pre-existing Chronic Myeloid Leukemia: The Role of Achieving Molecular Response and Treatment-Free Remission.
Pinlac V; Bonifacio L
Transplant Proc; 2024 Apr; 56(3):738-741. PubMed ID: 38538381
[TBL] [Abstract][Full Text] [Related]
26. Patient perceptions of treatment-free remission in chronic myeloid leukemia.
Villemagne Sanchez LA; O'Callaghan C; Gough K; Hall K; Kashima Y; Seymour JF; Schofield P; Ross DM
Leuk Lymphoma; 2018 Feb; 59(2):406-415. PubMed ID: 28617066
[TBL] [Abstract][Full Text] [Related]
27. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
[TBL] [Abstract][Full Text] [Related]
29. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
[TBL] [Abstract][Full Text] [Related]
30. Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective.
Saglio G; Sharf G; Almeida A; Bogdanovic A; Bombaci F; Čugurović J; Deekes N; Garcia-Gutiérrez V; de Jong J; Narbutas Š; Westerweel P; Zackova D
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):375-379. PubMed ID: 29753691
[TBL] [Abstract][Full Text] [Related]
31. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
32. SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML).
Mikhaeel S; Atallah E
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):333-339. PubMed ID: 36934065
[TBL] [Abstract][Full Text] [Related]
33. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
Claudiani S; Apperley JF; Szydlo R; Khan A; Nesr G; Hayden C; J Innes A; Dominy K; Foskett P; Foroni L; Khorashad J; Milojkovic D
Br J Haematol; 2021 Apr; 193(2):346-355. PubMed ID: 33368155
[TBL] [Abstract][Full Text] [Related]
34. The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia.
Conti RM; Padula WV; Becker RV; Salamone S
J Manag Care Spec Pharm; 2021 Aug; 27(8):1077-1085. PubMed ID: 34337991
[No Abstract] [Full Text] [Related]
35. Nilotinib in the treatment of chronic myeloid leukemia.
Sacha T; Saglio G
Future Oncol; 2019 Mar; 15(9):953-965. PubMed ID: 30547682
[TBL] [Abstract][Full Text] [Related]
36. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
37. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
[TBL] [Abstract][Full Text] [Related]
38. On the road to treatment-free remission in chronic myeloid leukemia: what about 'the others'?
Stagno F; Breccia M; Di Raimondo F
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1075-1081. PubMed ID: 32985290
[TBL] [Abstract][Full Text] [Related]
39. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
[TBL] [Abstract][Full Text] [Related]
40. Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy.
Borghi L; Rosti G; Maggi A; Breccia M; Di Bona E; Iurlo A; La Barba G; Sportoletti P; Albano F; Galimberti S; Rivellini F; Cambrin GR; Capodanno I; Cuneo A; Bonifacio M; Sica S; Arcaini L; Capochiani E; Minotto C; Ciceri F; Crugnola M; Di Caprio L; Supekar S; Elena C; Baccarani M; Vegni E
Front Oncol; 2021; 11():638689. PubMed ID: 34123791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]